Search Antibody Database

Found 1 matching record:

Displaying record number 4026

Download this epitope record as JSON.

Notes

Showing 1 of 1 note.

• CAP228-16H: V2-directed antibodies isolated from the RV144 vaccine trial correlated with reduced HIV-1 infection risk by interacting with positively charged residues at positions 168, 169, and 171 in V2. Here, van Eeden et al. isolate two antibody lineages (CAP228-16H/19F and CAP228–3D), similar to RV144 Abs CH58 and CH59, from infected subject CAP228, that mediate potent antibody-dependent cell-mediated cytotoxicity (ADCC). While in both CH58 and CH59 binding was restricted to two light chain genes, the new Ab lineages isolated in this study identify a third V2-reactive light chain gene, increasing the antibody repertoire potentially elicited by vaccination. These data helped in the understanding of the development of cross-reactive, V2-binding, antiviral Abs. The epitope binding profile of CAP228-16H was strikingly similar to CH58, with binding to K168, A/V172, Y/H173, L175,F176, K/R178, and D180. vanEeden2018 (ADCC, antibody binding site, antibody lineage)

References

Showing 1 of 1 reference.

Isolation Paper
vanEeden2018 Charmaine van Eeden, Constantinos Kurt Wibmer, Cathrine Scheepers, Simone I. Richardson, Molati Nonyane, Bronwen Lambson, Nonhlanhla N. Mkhize, Balakrishnan Vijayakumar, Zizhang Sheng, Sherry Stanfield-Oakley, Jinal N. Bhiman, Valerie Bekker, Tandile Hermanus, Batsirai Mabvakure, Arshad Ismail, M. Anthony Moody, Kevin Wiehe, Nigel Garrett, Salim Abdool Karim, Heini Dirr, Manuel A. Fernandes, Yasien Sayed, Lawrence Shapiro, Guido Ferrari, Barton F. Haynes, Penny L. Moore, and Lynn Morris. V2-Directed Vaccine-Like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. Cell Rep., 25(11):3123-3135.e6, 11 Dec 2018. PubMed ID: 30540944. Show all entries for this paper.